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STUDY PROTOCOL Open Access
Prophylactic platelet transfusion prior to
central venous catheter placement in
patients with thrombocytopenia: study
protocol for a randomised controlled trial
Emma K. van de Weerdt1,2,5* , Bart J. Biemond4, Sacha S. Zeerleder4, Krijn P. van Lienden3, Jan M. Binnekade1,
Alexander P. J. Vlaar1,2 and Study collaborative
Abstract
Background: Severe thrombocytopenia should be corrected by prophylactic platelet transfusion prior to central
venous catheter (CVC) insertion, according to national and international guidelines. Even though correction is thought
to prevent bleeding complications, evidence supporting the routine administration of prophylactic platelets is absent.
Furthermore, platelet transfusion bears inherent risk. Since the introduction of ultrasound-guided CVC placement, bleeding
complication rates have decreased. The objective of the current trial is, therefore, to demonstrate that omitting prophylactic
platelet transfusion prior to CVC placement in severely thrombocytopenic patients is non-inferior compared to prophylactic
platelet transfusion.
Methods/design: The PACER trial is an investigator-initiated, national, multicentre, single-blinded, randomised controlled,
non-inferior, two-arm trial in haematologic and/or intensive care patients with a platelet count of between 10 and 50 ×
109/L and an indication for CVC placement. Consecutive patients are randomly assigned to either receive 1 unit of platelet
concentrate, or receive no prophylactic platelet transfusion prior to CVC insertion. The primary endpoint is WHO grades 2–4
bleeding. Secondary endpoints are any bleeding complication, costs, length of intensive care and hospital stay and
transfusion requirements.
Discussion: This is the first prospective, randomised controlled trial powered to test the hypothesis of whether omitting
forgoing platelet transfusion prior to central venous cannulation leads to an equal occurrence of clinical relevant bleeding
complications in critically ill and haematologic patients with thrombocytopenia.
Trial registration: Nederlands Trial Registry, ID: NTR5653 (http://www.trialregister.nl/trialreg/index.asp). Registered on 27
January 2016. Currently recruiting. Randomisation commenced on 23 February 2016.
Keywords: Central venous catheter, Thrombocytopenia, Platelet count, Bleeding complication
Background
Central venous catheter (CVC) placement is a frequently
applied medical intervention that enables both monitoring
and treatment of patients [1, 2]. The inserted cannula pro-
vides central venous access either in the neck region
(subclavian vein or jugular vein) or groin region (femoral
vein). CVCs form an essential element of treatment in vari-
ous patient categories, mainly haematologic and intensive
care patients [1, 2]. The latter patient categories have an
elevated risk for a low platelet count (thrombocytopenia),
due to their treatment and the physiopathology of their
illnesses [3–5]. Thrombocytopenia is associated with an
increased bleeding risk for many invasive procedures [6].
However, abnormal traditional coagulation tests are known
to be a poor predictor of peri-procedural bleeding [7–9].
Current national and international guidelines are conflicting,
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most recent Dutch and UK guidelines support prophylactic
platelet transfusion below a platelet count of 50 × 109/L,
prior to CVC placement [10, 11]. Others support the admin-
istration of prophylactic platelet transfusion below a platelet
count of 20 × 109/L; however, the evidence supporting these
recommendations is of low quality [12, 13]. Current prophy-
lactic platelet transfusion practice prior to CVC placement
varies widely [14].
In the last decades, more has become known about
transfusion-related morbidity and mortality; platelet
transfusion bears a substantial risk for morbidity and mor-
tality, including transfusion-related acute lung injury
(TRALI), transfusion-associated cardiac overload (TACO),
allergic reactions, allo-immunisation and transfusion-
related infections [15–21]. In a prospective cohort study of
consecutive intensive care unit (ICU) patients receiving
blood transfusion products, 6% developed TACO [22]. In
the Netherlands, 0.32% of pooled platelet concentrates and
0.23% of apheresis platelet concentrate units are contami-
nated with bacteria [23]. Transfusion of platelets is an inde-
pendent risk factor for the onset of nosocomial infections
in ICU patients, with a hazard ratio of 1.40 (95% confidence
interval (CI) 1.2–1.8) [24]. Next to the burden of transfu-
sion exposure, blood products are expensive and scarce.
Critically ill and haematologic patients are at higher risk of
transfusion-related morbidity and mortality [15, 25].
Altogether, these insights in transfusion-related morbidity
and mortality have made platelet transfusion without a very
strict indication less desirable.
Recent retrospective studies suggest that the experience
of the physician and the technique used (ultrasound (US)
vs. landmark) rather than the platelet count predicts
bleeding complications [26–28]. The introduction of US
guidance for CVC placement was a major improvement
[29]. The use of US for CVC insertion results in a lower
number of puncture attempts, arterial puncture, haema-
toma pneumothorax and haematothorax [29–31]. One
meta-analysis showed a lower incidence of arterial punc-
ture with the use of US, namely 37/2009 (1.8%), compared
to 196/2018 (9.7%) with anatomical landmarks (RR 0.25,
95% CI 0.15 to 0.42). Also, the occurrence of haematoma
was reduced from 113/1512 (7.5%) to 24/1500 (1.6%), with
a RR 0.30 (95% CI 0.19 to 0.46) [31].
Consequently, recent retrospective studies suggest that
US-guided central venous cannulation can safely be per-
formed in patients with a platelet count above 20 × 10 9/L
[28, 32, 33]. In a study with 604 CVC placements, in 193
patients with acute leukemia, manual compression to stop
bleeding was required in eight patients, no major bleeding
was observed [28]. However, this study missed a control
group and the administration of prophylactic platelet trans-
fusion was not standardised, resulting in high risk of bias.
The current protocol describes the first randomised
controlled trial to evaluate the effect of prophylactic
platelet transfusion in haematologic and intensive care
patients in need of a CVC.
Methods/design
Study hypothesis
We hypothesise that the improved standards of CVC
placement, e.g. the use of US, make the need for correction
of thrombocytopenia prior to CVC placement obsolete.
Study objective
The primary objective is to demonstrate that the omis-
sion of prophylactic platelet transfusion in severely
thrombocytopenic patients does not increase the amount
of bleeding complications related to CVC placement.
Primary endpoint
A procedure-related relevant bleeding, occurring within 24
h after the procedure. A WHO grade of 2–4 (Additional
file 1) up to 24 h of randomisation is defined as relevant
bleeding.
Secondary endpoints
• Platelet transfusion requirements within 24 h of
CVC placement
• Number of RBC transfusions within 24 h of CVC
placement
• WHO grade-1 bleeding within 24 h of CVC
placement
• Haematoma size
• Haemoglobin level at 1 h and 24 h after CVC
placement
• Platelet transfusion increment
• HEME bleeding score (Additional file 1)
• Allergic transfusion reaction within 24 h
• Onset of acute lung injury within 48 h
• Length of hospital stay
• Costs
Design
The PACER trial is a randomised controlled, non-inferiority
trial on prophylactic platelet transfusion prior to CVC place-
ment in patients with severe thrombocytopenia. It is an
investigator-initiated, multicentre, parallel, randomised con-
trolled, two-arm trial in haematologic and/or intensive care
patients with thrombocytopenia and an indication for CVC
placement. The PACER trial will be conducted according to
the principles of the Declaration of Helsinki as stated in the
current version of Fortaleza, Brazil, 2013 [34] and in accord-
ance with the Medical Research Involving Human Subjects
Act (WMO). The Institutional Review Board of the
Academic Medical Centre, Amsterdam, the Netherlands,
approved the trial protocol under reference number
2015_27#B201662. The trial is registered at http://www.trial
register.nl/trialreg/admin/rctview.asp?TC=5653 (NTR5653).
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Intensive care patients will be provisionally included under a
strategy of deferred consent, which is explained in detail in
the ‘Consent’ section below. For patients at the Department
of Haematology, written informed consent is obtained prior
to randomisation. We adhered to the SPIRIT statement
(Additional file 2 SPIRIT checklist).
CONSORT diagram
The Consolidated Standards of Reporting Trials (CON-
SORT) diagram of the PACER study is presented in Fig. 1.
Consecutive thrombocytopenic patients who have an
indication for central venous catheterisation are screened.
Demographic data are registered regardless of meeting
enrolment criteria using a predefined screen log. If patients
are excluded for participation, the reason(s) for exclusion
are registered. For the screening of thrombocytopenia, rou-
tinely conducted laboratory values are used. The indication
for a CVC is determined at the physician’s discretion.
Setting
The PACER trial is a multicentre study performed in six
academic and five teaching hospitals in the Netherlands.
We plan to include 392 patients in 36 months, with a
potential limit of 462 patients to accommodate loss to
follow-up and possible dropout.
Study population
Thrombocytopenic patients with a platelet count of
10–50 × 109 are eligible for participation if a central line
is indicated. Both patients who need elective and
Fig. 1 PACER trial (Consolidated Standards of Reporting Trials (CONSORT)) Diagram. CONSORT diagram of PACER. For haematologic patients,
informed consent is required prior to randomisation. For the intensive care patients, randomisation takes place via deferred consent. If consent is
not obtained, data are excluded
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emergency line insertions are appropriate for randomisa-
tion. Both tunnelled and non-tunnelled CVCs are suit-
able for inclusion, as well as lines inserted for
continuous venovenous haemodiafiltration. Notably, pa-
tients requiring replacement of central catheters are also
eligible. Patients can participate in the study multiple
times; however, a patient can be randomised once per 24
h. The CVC should be expected to be in situ for at least
24 h to monitor 24-h bleeding complications. Therefore,
central lines for single plasmapheresis or the harvesting
of stem cells will not be included. All other indications
can be included, e.g. inotrope medication, lack of periph-
eral venous access, haemodialysis, haemodynamic moni-
toring, administration of irritating medication such as
chemotherapy. According to guidelines, patients with an
International Normalised Ratio (INR) of > 1.5 before line
placement are excluded [35]. However, patients are
eligible after correction of an elevated INR with fresh
frozen plasma or prothrombin concentrate. Non-adult
patients (age below 18 years) are excluded, as are
patients with a history of congenital or acquired coagula-
tion factor deficiency or bleeding diathesis. Also patients
on therapeutic anticoagulant therapy are excluded. Of
note, patients with a single platelet aggregation inhibitor
and/or therapeutic unfractionated heparin that is discon-
tinued at least 1 h prior to insertion are considered to
be eligible.
Consent
Informed consent will be obtained from all participants
or a legal representative in case the former is impossible.
As mentioned previously, this study involves two patient
categories. In haematologic patients, lines are usually
inserted electively for the administration of chemother-
apy. Therefore, informed consent will be obtained before
line placement. For the intensive care patient category,
obtaining informed consent prior to CVC insertion is
often not feasible. Therefore, for the intensive care
setting patients may be included using the deferred con-
sent procedure. We will randomise each patient at the
ICU who meets the inclusion criteria directly before
CVC placement. Informed consent from the legal repre-
sentative will be requested as soon as possible. If
informed consent is denied by a legal representative, the
patient is excluded and data will no longer be used.
Thenceforth, the patient is transfused according to the
policy of the attending physician. If a patient dies before
informed consent can be obtained, the data are used [36].
Randomisation and blinding
Randomisation will be performed using a dedicated,
password-protected, SSL-encrypted website with ALEA®
software (TenALEA consortium, Amsterdam, The
Netherlands). The researcher randomises the patient.
Random block sizes are used. Block randomisation will
be stratified per centre and per patient population (ICU
vs. haematologic patients). Tunnelled lines are stratified
per centre. Also, lines placed for dialysis/CVVH are
stratified from central lines placed for other indications.
This stratification takes place since dialysis/CVVH cath-
eters are larger-bore catheters, made of stiffer materials
and bear increased risk for bleeding [37].
The proceduralist, the physician who inserts the cath-
eter, is blinded for treatment allocation. This blinding
takes place to prevent bias in ordering platelet transfu-
sion in case of a peri-procedural bleeding complication.
The proceduralist is not directly involved in patient care
of the included patient. Blinding is not feasible for the
patient and the treating medical staff. Obtained photo-
graphs of the insertion site will be analysed for haema-
toma size and bleeding post hoc. This provides an
additional blinded bleeding outcome.
Treatment arms
Included patients will be randomised into one of two
groups. One group of patients will be allocated to not
receiving platelet transfusion prior to placement of the
CVC, this is the experimental group. The other group of
patients will be transfused with 1 unit of platelet
concentrate prior to placement of the catheter, this is
the comparison group. All platelet products will be man-
ufactured, screened and stored according to local Dutch
standards, (Sanquin Blood Bank). Platelet concentrates
are prepared from pooled buffy coats from five donors,
and re-suspended in plasma, after which pooled platelet
concentrates are leukoreduced by filtration. All platelet
products are stored, with gentle agitation at 20–24 °C,
for up to 7 days in the Netherlands. All other care will
be according to standard practice as indicated by the
treating physician.
Central venous catheter placement
All CVCs will be inserted percutaneously, under real-
time US guidance, using the Seldinger technique. In the
transfusion arm, catheters will be inserted as soon as
possible after administration of 1 unit of platelet con-
centrate. The type of US device, catheters and (local)
anaesthesia used is according to local hospital proto-
cols. The puncture location will be determined by the
puncturing physician. All procedures will be performed
by experienced physicians, e.g. at least 50 previous line
placements [38]. Proceduralists can be experienced
residents or consultant physicians in intensive care,
anaesthesiology, haematology, (interventional) radi-
ology and surgery. Procedural details, such as arterial
puncture, vein lesion and number of puncture attempts
are recorded.
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Bleeding complications
Bleeding complications will be scored using WHO
grades of bleeding specified for CVC placement, which
are defined in Additional file 1. The WHO bleeding
score is adapted according to Zeidler [28]. Grade 1
consists of mild symptoms not requiring any interven-
tion; for example, local haematoma formation or wound
oozing. Grade 2 bleeding is defined as mild symptoms
requiring interventions, without haemodynamic instabil-
ity or red blood cell (RBC) transfusion. For the current
study, this includes procedure-related bleeding that
requires more than 20 min of manual compression to
stop. Grade 3 bleeding is defined as procedure-related
bleeding requiring red cell transfusion. Grade 4 bleeding
is defined as bleeding associated with hemodynamic
instability or death, defined as CVC-related bleeding
associated with severe hemodynamic instability
(hypotension; > 50 mmHg fall or > 50% decrease in either
systolic or diastolic blood pressure, with associated tachy-
cardia (heart rate increase of > 20% for 20 min) and re-
quiring RBC transfusion over routine transfusion needs or
fatal bleeding [39].
Furthermore, a distinction will be made between minor
and major bleeding. Minor bleeding is defined as WHO
bleeding scale grade 1 or 2. Major bleeding is defined as
WHO grade 3 or 4 bleeding. The proceduralist can ad-
minister rescue platelets at clinical indication. Rescue
platelet concentrate can be given irrespective of treatment
allocation, for which the proceduralist remains blinded.
In case of post-procedural bleeding, physicians are
encouraged to undertake the following steps:
1. Inspection of the insertion site
2. Apply manual compression, for a maximum duration
of 20 min
3. Consider a skin suture at the insertion site
4. Consider rescue platelet transfusion
5. Consider the possibility of a radiological of surgical
intervention
Protocol violation
If platelet concentrate is administered to patients assigned
to not receiving platelet concentrate, patients will not be
excluded. Reasons for additional transfusion are noted. Pa-
tients will be analysed according to intention-to-treat and
per-protocol analyses. If line placement is unsuccessful
due to technical reasons, data will also be analysed accord-
ing to the intention-to-treat analysis. If blinding of the
proceduralist is violated, this will be noted; however, pa-
tient data will not be excluded. If the 24-h time point is
not completed, due to a CVC that is in situ for less than
24 h, or in the case that a patient deceases within this
timeframe, obtained data will be analysed using missing
data for the 24-h time point.
Participant timeline and study flowchart
The participant timeline is presented in Fig. 2. The
primary outcome of the study is procedure-related
WHO bleeding grades 2–4, occurring within 24 h
after the procedure.
Secondary endpoints are subdivided into clinical out-
come variables and health-economic-outcome variables.
WHO grade-1 bleedings and subdivision on minor and
major bleeding are scored as secondary outcome.
Another clinical outcome variable is the validated HEME
bleeding score [40]. Also, photographs of the insertion
site at different time points are blindly scored. Other
clinical variables include ICU and hospital length of stay
(LOS), ICU and hospital mortality, transfusion require-
ments and occurrence of transfusion reactions such as
TRALI and allergic reactions. Next to descriptive statis-
tics, the effect of prophylactic platelet transfusion on the
primary and secondary outcomes will be analysed using
multiple logistic regression for patient-, procedural-,
catheter- and transfusion-related characteristics. In
patients receiving platelet transfusion, patient- and
transfusion-related factors will be analysed to assess the
relation to post-transfusion platelet increment. To inves-
tigate the relationship between bleeding events and
platelet count (post-transfusion platelet count if applic-
able) we divide platelet count into five groups: 10–20,
20–30, 30–40, 40–50 and above 50. P values of 0.05 will
be accepted as statistically significant, values will be re-
ported with and without correction for multiple testing.
Health-economic outcomes are calculated in the cost-
effectiveness analysis, where costs per procedure-related
bleeding event (primary clinical outcome) will be esti-
mated. The economic evaluation will estimate costs
(saved) per PC transfusion avoided. Results will be
extrapolated to the national level to estimate the total
impact on the health care budget per annum for the
Netherlands in terms of cost reduction and increase in
procedure-related bleeding events.
Data collection
Inclusion is based on platelet count determined in the 24
h prior to randomisation. Baseline parameters, such as
age, gender, height, weight and Body Mass Index (BMI),
are collected. Recorded clinical parameters include date of
admission, diagnosis, cause of thrombocytopenia, indica-
tion for CVC, use of defined confounding medication,
hepatic- and kidney failure, diffuse intravascular coagulop-
athy and fever. For intensive care patients, also APACHE
score, admission diagnosis and information about setting
during admission are obtained. For haematologic patients,
information about the haematologic condition and the
phase of therapy is collected. In all patients, the most re-
cent PT (INR), aPTT and haemoglobin levels, prior to
randomisation are recorded. Information about the CVC,
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such as type, indication and diameter, is collected. Proced-
ural details, such as insertion site, number of punctures,
inadvertent arterial puncture, manual compression and
the administration of ‘rescue platelets’, are recorded.
According to standard care, blood is collected at 1 h and
24 h after CVC placement. In this way the effect of the
platelet concentrate, if applicable, can be measured. A
photographic image of the insertion site is taken prior to
CVC placement, as well as directly post procedural and at
1 and 24 h after CVC placement. Clinical bleeding will be
assessed at these same time points. All administered trans-
fusion of blood products will be registered, as well as their
clinical indication. All radiologic and surgical interven-
tions will be documented.
Follow-up
The follow-up time for the primary outcome is 24 h.
Patient information about both ICU and hospital
discharge or death, whichever comes first, are collected.
Data management
An eCRF for the PACER trial in Open Clinica is developed.
All participating centres have 24-h access to the eCRF.
Data can be entered continuously for all participating
patients. The principle investigator has access to the filled-
out eCRFs. If data are entered incompletely or incorrectly,
the principle investigator can contact the participating cen-
tres for clarification.
Statistical considerations
We target to include 392 patients, with a potential limit of
462 patients to accommodate loss to follow-up and a pos-
sible dropout. The expected rate of severe peri-procedural
bleeding incidents is around 0% [28, 33, 41–43]. Major
bleeding is defined as WHO grade 3: gross blood loss re-
quiring transfusion, or grade 4: debilitating blood loss
(Additional file 1: Table S1). Considering the low compli-
cation occurrence, sample sizes that are by far unrealistic
within the proposed study are required to demonstrate
non-inferiority with an acceptable non-inferiority limit of
(< 1%). We therefore also include WHO grade-2 bleedings
in the definition of the primary outcome. As the observed
bleeding events will concern predominantly grade-2
bleedings, and probably no or only incidental bleedings
with more severe grades 3 or 4, an upper limit reflecting
an absolute risk increase of 2.5% more bleeding events as
the criterion to statistically demonstrate non-inferiority is
considered both statistical and clinical acceptable. The
STUDY PERIOD
Enrolment Allocation Post-allocation Close-out






Platelet transfusion or 
Restrictive X
Insertion of CVC X
ASSESSMENTS:
Laboratory values, platelet 
count and hemoglobin X X X
Assessment of catheter 
insertion site X X X X
Transfusion reaction 
(TRALI, allergic reaction) .
Transfusions outside study 
protocol
Alive at day 28
X X
Fig. 2 Informed consent will be obtained from all participants or a legal representative in case the former is impossible. Intensive Care patients
may be included using the deferred consent procedure. We will randomise each patient at the intensive care unit (ICU) who meets the inclusion
criteria directly before CVC placement. Informed consent from the legal representative will be requested as soon as possible. If a patient deceases
before informed consent can be obtained, data is used
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sample size is increased by 2% to correct for loss to
follow-up and by 15% to correct for dropouts, e.g. refusal
of consent. Using a non-inferiority design, a sample size of
196 patients (per arm) and a percentage bleeding events
of 1% in the control group and an expected percentage
bleeding events of 1% in the experimental group will re-
sult in a power of 80% to exclude that there is a significant
bleeding rate in the experimental arm (> 3.5% bleedings,
absolute risk increase 2.5%, two group t test with a 0.05
two-sided significance level). As we do not anticipate any
loss to follow-up – considering the short time-span of the
study – we therefore intend to enrol 392 patients in total.
Statistical analysis
Statistical analysis will be based both on an intention-to-treat
principle and a per-protocol approach. Baseline assessments
and outcome parameters will be summarised using simple
descriptive statistics. The main analysis focusses on a com-
parison between the trial treatment groups of the primary
outcome, the occurrence of relevant bleedings, expressed in a
relative risk estimate and absolute risk increase, with the asso-
ciated 95% upper confidence limit. Non-inferiority is demon-
strated if this interval does not exceed the non-inferiority
limit of 2.5% absolute difference in favour of transfusion.
Withdrawal and replacement of individual patients
Subjects can leave the study at any time for any reason if
they wish to do so without any consequences. The investi-
gator can decide to withdraw a subject from the study for
urgent medical reasons. When deferred consent is not
obtained after randomisation and provisional inclusion of
a patient, the randomised subject will be replaced. These
cases will be recorded in the randomisation log without
patient-specific data. The randomisation subject will be
replaced in order to retain properly distributed random-
isation groups and stratification.
Study organisation
The Steering Committee is composed of the principal
investigators, the coordinating investigator and the local
investigators in the participating ICUs and haematology
departments. The coordinating investigator is respon-
sible for administrative management and communica-
tion with the local investigators and provides assistance
to the participating clinical sites in trial management,
record keeping and data management. The coordinating
investigator helps in setting up local training in the
participating centres to ensure the study is conducted
according to the ICH-GCP guidelines, to guaranty integ-
rity of data collection and to ensure timely completion
of the case report forms. The local investigators provide
structural and scientific leadership. They guarantee the
integrity of data collection and ensure timely completion
of the case report forms.
An independent monitor is installed to perform study
monitoring. Remote monitoring by means of queries on
the database will be done by a statistician and analysed
by the monitor to signalise early aberrant patterns,
trends, issues with consistency or credibility and other
anomalies. On-site monitoring will comprise controlling
presence and completeness of the research dossier and
the informed consent forms, source data checks will be
performed in the files of the first three patients of each
participating centre, followed by at least 10% of files.
Each centre will be visited at least once every year.
An independent Date Safety and Monitoring Board
watches over the ethics of conducting the study in accord-
ance with the declaration of Helsinki, monitors safety pa-
rameters and the overall conduct of the study. The DSMB
is composed of three independent individuals (Dr. MGW
Dijkgraaf, Dr. MCA Müller, Prof. Dr. JJ Zwaginga). The
DSMB will meet by conference calls. The first took place
before the first inclusion. Subsequent to this meeting the
DSMB will meet approximately every 6 months. Also, a
meeting will be scheduled after half of the total number of
patients are enrolled.
As severe bleeding complications after central venous
catheterisation are extremely rare, no bleeding-related ser-
ious adverse event is expected. All unexpected adverse
events will be reported to the DSMB. Any report and/or
advice of the DSMB will be send to the sponsor of the
study, the Academic Medical Centre, Amsterdam, The
Netherlands. Should the sponsor decide not to fully imple-
ment advices of the DSMB, the sponsor will send the ad-
vice to the reviewing Institutional Review Board, including
a note to substantiate why (part of) the advice of the
DSMB will not be followed.
Discussion
This is the first randomised trial that investigates the safety
of a lower platelet concentrate transfusion threshold prior
to CVC placement, in a non-inferiority design. If this trial
concludes that omission of prophylactic platelets in patients
with a platelet count of 10 × 109/L and higher is safe, guide-
lines that advise routine administration of platelet concen-
trate might be adjusted. For the Netherlands alone, we
calculated that a transfusion threshold of 10 × 109/L for
prophylactic platelet transfusion prior CVC placement
instead of 50 × 109/L could lead to a cost reduction of 9.2
million euros per year [44].
Central venous catheterisation access is a frequently
applied medical intervention; more than five million
catheters are inserted in the United States each year [45,
46]. A peripherally inserted central catheter (PICC line)
is often not an adequate alternative for percutaneous
central vein cannulation because it bears an increased
risk for thrombosis, especially in haemato-oncologic and
critically ill patients [47].
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Various factors associated with bleeding complications
after CVC placement have been identified [29, 38, 48, 49].
The risk of bleeding after central venous catheterisation is
multifactorial and is composed of procedural, patient and
physician characteristics. Number of attempts, inadvertent
arterial puncture, vein size, vein lesion, patient compli-
ance, obesity and pulmonary hyperinflation have also been
associated with bleeding risk [46, 50]. Therefore, it is diffi-
cult to assess the isolated effect of thrombocytopenia.
Randomisation will divide patient-related factors evenly
over both treatment arms. All lines are placed by experi-
enced proceduralists, under real-time US guidance.
A concern regarding safety could be the occurrence of
major bleeding in the no-platelet-concentrate-transfusion
arm of the study. Based on previous observational studies
we believe that the risk for serious complications is limited.
We monitor the patients intensively and rescue platelet
concentrate is available. Prolonged manual compression, or
a suture at the insertion site are suggested as safe and min-
imally invasive interventions to stop prolonged bleeding
[28, 42, 51]. In contrast, patients randomised to not receiv-
ing platelet concentrate are not exposed to the inherent risk
of platelet transfusion.
A potential shortcoming of the current trial is the het-
erogeneous patient population having different causes of
thrombocytopenia. Our study includes the two patient
populations in which thrombocytopenia and central ven-
ous cannulisation are most frequent. We believe that
this is also is a strength of our study, allowing results to
be extrapolated to various patients categories.
In conclusion, this is the first prospective, randomised
controlled, non-inferiority trial powered to test the hy-
pothesis whether not correcting thrombocytopenia prior
to central venous cannulation does not lead to an in-
creased occurrence of bleeding complications in critic-




Additional file 1: Table S1. WHO bleeding score. Specified for central
venous catheter-related bleeding. All bleeding must be central venous
catheter related, within 24 h after insertion. (DOC 29 kb)
Additional file 2: SPIRIT 2013 Checklist: recommended items to address
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